Argenx surges after hit in nerve disorder
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
Bridgebio finally gets its cardiomyopathy win
A convincing hit puts approval, and potentially partnerships, on the table.
Caribou’s allogeneic Car meets a six-month bar
But relapses are still frequent – a problem that, curiously, higher dosing has not assuaged.
A chronic disappointment for Viridian
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.
Astrazeneca and Daiichi’s big reveal disappoints
High level results on datopotamab raise safety and efficacy concerns, putting billion-dollar sales forecasts at risk.